Davies JC - Search Results

1

Clinical characteristics of Pseudomonas and Aspergillus co-infected cystic fibrosis patients: A UK registry study.

Hughes DA, Archangelidi O, Coates M, Armstrong-James D, Elborn SJ, Carr SB, Davies JC. Hughes DA, et al. Among authors: davies jc. J Cyst Fibros. 2022 Jan;21(1):129-135. doi: 10.1016/j.jcf.2021.04.007. Epub 2021 May 3. J Cyst Fibros. 2022. PMID: 33958279 Free article.

2

Reduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition.

Davies J, Dewar A, Bush A, Pitt T, Gruenert D, Geddes DM, Alton EW. Davies J, et al. Eur Respir J. 1999 Mar;13(3):565-70. doi: 10.1183/09031936.99.13356599. Eur Respir J. 1999. PMID: 10232427 Free article.

3

Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence.

Scheid P, Kempster L, Griesenbach U, Davies JC, Dewar A, Weber PP, Colledge WH, Evans MJ, Geddes DM, Alton EW. Scheid P, et al. Among authors: davies jc. Eur Respir J. 2001 Jan;17(1):27-35. doi: 10.1183/09031936.01.17100270. Eur Respir J. 2001. PMID: 11307750 Free article.

4

Use of cough swabs in a cystic fibrosis clinic.

Equi AC, Pike SE, Davies J, Bush A. Equi AC, et al. Arch Dis Child. 2001 Nov;85(5):438-9. doi: 10.1136/adc.85.5.438. Arch Dis Child. 2001. PMID: 11668115 Free PMC article.

5

Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence.

Davies JC. Davies JC. Paediatr Respir Rev. 2002 Jun;3(2):128-34. doi: 10.1016/s1526-0550(02)00003-3. Paediatr Respir Rev. 2002. PMID: 12297059 Review.

6

Airway surface pH in subjects with cystic fibrosis.

McShane D, Davies JC, Davies MG, Bush A, Geddes DM, Alton EW. McShane D, et al. Among authors: davies mg, davies jc. Eur Respir J. 2003 Jan;21(1):37-42. doi: 10.1183/09031936.03.00027603. Eur Respir J. 2003. PMID: 12570106 Free article.

7

Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation.

Davies G, McShane D, Davies JC, Bush A. Davies G, et al. Among authors: davies jc. Pediatr Pulmonol. 2003 Apr;35(4):253-6. doi: 10.1002/ppul.10262. Pediatr Pulmonol. 2003. PMID: 12629620

8

Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles.

Davies JC, Turner MW, Klein N; London MBL CF Study Group. Davies JC, et al. Eur Respir J. 2004 Nov;24(5):798-804. doi: 10.1183/09031936.04.00055404. Eur Respir J. 2004. PMID: 15516675 Free article.

9

Exploring the mechanisms of macrolides in cystic fibrosis.

Equi AC, Davies JC, Painter H, Hyde S, Bush A, Geddes DM, Alton EW. Equi AC, et al. Among authors: davies jc. Respir Med. 2006 Apr;100(4):687-97. doi: 10.1016/j.rmed.2005.07.016. Epub 2005 Sep 26. Respir Med. 2006. PMID: 16185859 Free article.

10

Bronchoscopy following diagnosis with cystic fibrosis.

Hilliard TN, Sukhani S, Francis J, Madden N, Rosenthal M, Balfour-Lynn I, Bush A, Davies JC. Hilliard TN, et al. Among authors: davies jc. Arch Dis Child. 2007 Oct;92(10):898-9. doi: 10.1136/adc.2006.105825. Epub 2006 Nov 6. Arch Dis Child. 2007. PMID: 17088336 Free PMC article.

11

Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis.

Weisner AM, Chart H, Bush A, Davies JC, Pitt TL. Weisner AM, et al. Among authors: davies jc. J Med Microbiol. 2007 May;56(Pt 5):670-674. doi: 10.1099/jmm.0.46833-0. J Med Microbiol. 2007. PMID: 17446292

12

Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis.

Kozlowska WJ, Bush A, Wade A, Aurora P, Carr SB, Castle RA, Hoo AF, Lum S, Price J, Ranganathan S, Saunders C, Stanojevic S, Stroobant J, Wallis C, Stocks J; London Cystic Fibrosis Collaboration. Kozlowska WJ, et al. Am J Respir Crit Care Med. 2008 Jul 1;178(1):42-9. doi: 10.1164/rccm.200710-1599OC. Epub 2008 Apr 10. Am J Respir Crit Care Med. 2008. PMID: 18403721

13

Pseudomonas aeruginosa, cyanide accumulation and lung function in CF and non-CF bronchiectasis patients.

Ryall B, Davies JC, Wilson R, Shoemark A, Williams HD. Ryall B, et al. Among authors: davies jc. Eur Respir J. 2008 Sep;32(3):740-7. doi: 10.1183/09031936.00159607. Epub 2008 May 14. Eur Respir J. 2008. PMID: 18480102 Free article.

14

Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function.

Simmonds NJ, D'Souza L, Roughton M, Alton EW, Davies JC, Hodson ME. Simmonds NJ, et al. Among authors: davies jc. Eur Respir J. 2011 May;37(5):1076-82. doi: 10.1183/09031936.00079010. Epub 2010 Sep 16. Eur Respir J. 2011. PMID: 20847077 Free article.

15

Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis.

Aurora P, Stanojevic S, Wade A, Oliver C, Kozlowska W, Lum S, Bush A, Price J, Carr SB, Shankar A, Stocks J; London Cystic Fibrosis Collaboration. Aurora P, et al. Am J Respir Crit Care Med. 2011 Mar 15;183(6):752-8. doi: 10.1164/rccm.200911-1646OC. Epub 2010 Oct 8. Am J Respir Crit Care Med. 2011. PMID: 20935113

16

Bronchoscopy in cystic fibrosis infants diagnosed by newborn screening.

Stafler P, Davies JC, Balfour-Lynn IM, Rosenthal M, Bush A. Stafler P, et al. Among authors: davies jc. Pediatr Pulmonol. 2011 Jul;46(7):696-700. doi: 10.1002/ppul.21434. Epub 2011 Mar 1. Pediatr Pulmonol. 2011. PMID: 21365781

17

Basic science for the chest physician: Pseudomonas aeruginosa and the cystic fibrosis airway.

Williams HD, Davies JC. Williams HD, et al. Among authors: davies jc. Thorax. 2012 May;67(5):465-7. doi: 10.1136/thoraxjnl-2011-201498. Epub 2012 Mar 1. Thorax. 2012. PMID: 22382597 Review. No abstract available.

18

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordoñez CL, Ahrens R; VX08-770-103 (ENVISION) Study Group. Davies JC, et al. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25. doi: 10.1164/rccm.201301-0153OC. Am J Respir Crit Care Med. 2013. PMID: 23590265 Free PMC article. Clinical Trial.

19

Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis.

Fayon M, Kent L, Bui S, Dupont L, Sermet I; European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee. Fayon M, et al. Eur Respir J. 2014 Feb;43(2):610-26. doi: 10.1183/09031936.00017713. Epub 2013 Jul 11. Eur Respir J. 2014. PMID: 23845715 Free article. Review.

20

Lung clearance index: evidence for use in clinical trials in cystic fibrosis.

Kent L, Reix P, Innes JA, Zielen S, Le Bourgeois M, Braggion C, Lever S, Arets HG, Brownlee K, Bradley JM, Bayfield K, O'Neill K, Savi D, Bilton D, Lindblad A, Davies JC, Sermet I, De Boeck K; European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) Standardisation Committee. Kent L, et al. Among authors: davies jc. J Cyst Fibros. 2014 Mar;13(2):123-38. doi: 10.1016/j.jcf.2013.09.005. Epub 2013 Dec 5. J Cyst Fibros. 2014. PMID: 24315208 Free article. Review.

21

How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis.

Ahmed B, Bush A, Davies JC. Ahmed B, et al. Among authors: davies jc. Arch Dis Child Educ Pract Ed. 2014 Oct;99(5):181-7. doi: 10.1136/archdischild-2012-303408. Epub 2013 Dec 12. Arch Dis Child Educ Pract Ed. 2014. PMID: 24334311 Review.

22

Cyanide levels found in infected cystic fibrosis sputum inhibit airway ciliary function.

Nair C, Shoemark A, Chan M, Ollosson S, Dixon M, Hogg C, Alton EW, Davies JC, Williams HD. Nair C, et al. Among authors: davies jc. Eur Respir J. 2014 Nov;44(5):1253-61. doi: 10.1183/09031936.00097014. Epub 2014 Sep 3. Eur Respir J. 2014. PMID: 25186256 Free article.

23

Does mass spectrometric breath analysis detect Pseudomonas aeruginosa in cystic fibrosis?

Pabary R, Huang J, Kumar S, Alton EW, Bush A, Hanna GB, Davies JC. Pabary R, et al. Among authors: davies jc. Eur Respir J. 2016 Mar;47(3):994-7. doi: 10.1183/13993003.00944-2015. Epub 2016 Feb 4. Eur Respir J. 2016. PMID: 26846826 Free article. No abstract available.

24

Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations.

Vermeulen F, Le Camus C, Davies JC, Bilton D, Milenković D, De Boeck K. Vermeulen F, et al. Among authors: davies jc. J Cyst Fibros. 2017 Jan;16(1):36-40. doi: 10.1016/j.jcf.2016.02.015. Epub 2016 Mar 17. J Cyst Fibros. 2017. PMID: 26996268 Free article. Clinical Trial.

25

New drug developments in the management of cystic fibrosis lung disease.

Turnbull AR, Davies JC. Turnbull AR, et al. Among authors: davies jc. Expert Opin Pharmacother. 2016 Jun;17(8):1103-12. doi: 10.1517/14656566.2016.1157582. Epub 2016 Mar 28. Expert Opin Pharmacother. 2016. PMID: 27017976 Review.

26

Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.

Lund-Palau H, Turnbull AR, Bush A, Bardin E, Cameron L, Soren O, Wierre-Gore N, Alton EW, Bundy JG, Connett G, Faust SN, Filloux A, Freemont P, Jones A, Khoo V, Morales S, Murphy R, Pabary R, Simbo A, Schelenz S, Takats Z, Webb J, Williams HD, Davies JC. Lund-Palau H, et al. Among authors: davies jc. Expert Rev Respir Med. 2016 Jun;10(6):685-97. doi: 10.1080/17476348.2016.1177460. Epub 2016 May 13. Expert Rev Respir Med. 2016. PMID: 27175979 Free article. Review.

27

Cystic fibrosis in 2016: considerable progress, but much more to do.

Davies JC. Davies JC. Lancet Respir Med. 2016 Dec;4(12):943-945. doi: 10.1016/S2213-2600(16)30378-2. Epub 2016 Nov 22. Lancet Respir Med. 2016. PMID: 27890501 No abstract available.

28

Developments in multiple breath washout testing in children with cystic fibrosis.

Saunders C, Bayfield K, Irving S, Short C, Bush A, Davies JC. Saunders C, et al. Among authors: davies jc. Curr Med Res Opin. 2017 Apr;33(4):613-620. doi: 10.1080/03007995.2016.1268999. Epub 2017 Feb 2. Curr Med Res Opin. 2017. PMID: 27931123 Review.

29

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.

Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Flume PA, et al. Among authors: davies jc. J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24. J Cyst Fibros. 2018. PMID: 28651844 Free article.

30

Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Smith WD, Bardin E, Cameron L, Edmondson CL, Farrant KV, Martin I, Murphy RA, Soren O, Turnbull AR, Wierre-Gore N, Alton EW, Bundy JG, Bush A, Connett GJ, Faust SN, Filloux A, Freemont PS, Jones AL, Takats Z, Webb JS, Williams HD, Davies JC. Smith WD, et al. Among authors: davies jc. FEMS Microbiol Lett. 2017 Aug 1;364(14). doi: 10.1093/femsle/fnx121. FEMS Microbiol Lett. 2017. PMID: 28854668 Review.

31

Where are we with transformational therapies for patients with cystic fibrosis?

De Boeck K, Davies JC. De Boeck K, et al. Among authors: davies jc. Curr Opin Pharmacol. 2017 Jun;34:70-75. doi: 10.1016/j.coph.2017.09.005. Epub 2017 Oct 6. Curr Opin Pharmacol. 2017. PMID: 28992608 Review.

32

Pooling of bronchoalveolar lavage in children with cystic fibrosis does not adversely affect the microbiological yield or sensitivity in detecting pulmonary inflammation.

McNally P, O'Rourke J, Fantino E, Chacko A, Pabary R, Turnbull A, Grant T, O'Sullivan N, Wainwright C, Linnane B, Davies JC, Sly PD. McNally P, et al. Among authors: davies jc. J Cyst Fibros. 2018 May;17(3):391-399. doi: 10.1016/j.jcf.2017.10.016. Epub 2017 Nov 20. J Cyst Fibros. 2018. PMID: 29157921 Free article.

33

Impact of T2R38 Receptor Polymorphisms on Pseudomonas aeruginosa Infection in Cystic Fibrosis.

Turnbull AR, Murphy R, Behrends V, Lund-Palau H, Simbo A, Mariveles M, Alton EWFW, Bush A, Shoemark A, Davies JC. Turnbull AR, et al. Among authors: davies jc. Am J Respir Crit Care Med. 2018 Jun 15;197(12):1635-1638. doi: 10.1164/rccm.201711-2365LE. Am J Respir Crit Care Med. 2018. PMID: 29481289 Free PMC article. No abstract available.

34

Children with cystic fibrosis demonstrate no respiratory immunological, infective or physiological, consequences of vitamin D deficiency.

Thursfield RM, Naderi K, Leaver N, Rosenthal M, Alton EWFW, Bush A, Davies JC. Thursfield RM, et al. Among authors: davies jc. J Cyst Fibros. 2018 Sep;17(5):657-665. doi: 10.1016/j.jcf.2018.02.011. Epub 2018 Apr 7. J Cyst Fibros. 2018. PMID: 29631774 Free article.

35

Predicting the Future of Cystic Fibrosis Lung Disease: Gene Expression Holds Some of the Answers.

Edmondson C, Davies JC. Edmondson C, et al. Among authors: davies jc. Ann Am Thorac Soc. 2018 May;15(5):556-557. doi: 10.1513/AnnalsATS.201802-098ED. Ann Am Thorac Soc. 2018. PMID: 29714098 Free article. No abstract available.

36

Outdoor air pollution and cystic fibrosis.

Brugha R, Edmondson C, Davies JC. Brugha R, et al. Among authors: davies jc. Paediatr Respir Rev. 2018 Sep;28:80-86. doi: 10.1016/j.prrv.2018.03.005. Epub 2018 Apr 11. Paediatr Respir Rev. 2018. PMID: 29793860

37

Metabolic Phenotyping and Strain Characterisation of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients Using Rapid Evaporative Ionisation Mass Spectrometry.

Bardin EE, Cameron SJS, Perdones-Montero A, Hardiman K, Bolt F, Alton EWFW, Bush A, Davies JC, Takáts Z. Bardin EE, et al. Among authors: davies jc. Sci Rep. 2018 Jul 19;8(1):10952. doi: 10.1038/s41598-018-28665-7. Sci Rep. 2018. PMID: 30026575 Free PMC article.

38

New anti-pseudomonal agents for cystic fibrosis- still needed in the era of small molecule CFTR modulators?

Davies JC, Martin I. Davies JC, et al. Expert Opin Pharmacother. 2018 Aug;19(12):1327-1336. doi: 10.1080/14656566.2018.1505864. Epub 2018 Aug 12. Expert Opin Pharmacother. 2018. PMID: 30101632 Review.

39

Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review.

Dobra R, Edmondson C, Hughes D, Martin I, Davies JC. Dobra R, et al. Among authors: davies jc. Paediatr Drugs. 2018 Dec;20(6):555-566. doi: 10.1007/s40272-018-0315-z. Paediatr Drugs. 2018. PMID: 30328089 Review.

40

Longitudinal development of the airway microbiota in infants with cystic fibrosis.

Ahmed B, Cox MJ, Cuthbertson L, James P, Cookson WOC, Davies JC, Moffatt MF, Bush A. Ahmed B, et al. Among authors: davies jc. Sci Rep. 2019 Mar 26;9(1):5143. doi: 10.1038/s41598-019-41597-0. Sci Rep. 2019. PMID: 30914718 Free PMC article. Clinical Trial.

41

Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition.

Southern KW, Barben J, Gartner S, Munck A, Castellani C, Mayell SJ, Davies JC, Winters V, Murphy J, Salinas D, McColley SA, Ren CL, Farrell PM. Southern KW, et al. Among authors: davies jc. J Cyst Fibros. 2019 Nov;18(6):778-780. doi: 10.1016/j.jcf.2019.04.010. Epub 2019 Apr 24. J Cyst Fibros. 2019. PMID: 31027826 Free article. No abstract available.

42

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group. Rosenfeld M, et al. Among authors: davies jc. J Cyst Fibros. 2019 Nov;18(6):838-843. doi: 10.1016/j.jcf.2019.03.009. Epub 2019 Apr 30. J Cyst Fibros. 2019. PMID: 31053538 Free PMC article. Clinical Trial.

43

Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials.

Dobra R, Scott S, Davies JC, Simmonds NJ. Dobra R, et al. Among authors: davies jc. J Cyst Fibros. 2019 Sep;18(5):e45-e46. doi: 10.1016/j.jcf.2019.04.008. Epub 2019 May 3. J Cyst Fibros. 2019. PMID: 31060801 Free article. No abstract available.

44

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).

Davies JC, Van de Steen O, van Koningsbruggen-Rietschel S, Drevinek P, Derichs N, McKone EF, Kanters D, Allamassey L, Namour F, de Kock H, Conrath K. Davies JC, et al. J Cyst Fibros. 2019 Sep;18(5):693-699. doi: 10.1016/j.jcf.2019.05.006. Epub 2019 May 27. J Cyst Fibros. 2019. PMID: 31147302 Free article. Clinical Trial.

45

Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis.

Turnbull AR, Pyle CJ, Patel DF, Jackson PL, Hilliard TN, Regamey N, Tan HL, Brown S, Thursfield R, Short C, Mc Fie M, Alton EWFW, Gaggar A, Blalock JE, Lloyd CM, Bush A, Davies JC, Snelgrove RJ. Turnbull AR, et al. Among authors: davies jc. J Cyst Fibros. 2020 Jan;19(1):40-48. doi: 10.1016/j.jcf.2019.05.017. Epub 2019 Jun 5. J Cyst Fibros. 2020. PMID: 31176670 Free PMC article.

46

Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.

Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T; European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’; Amaral MD, de Boeck K, Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T. Davies JC, et al. J Cyst Fibros. 2019 Sep;18(5):677-684. doi: 10.1016/j.jcf.2019.06.011. Epub 2019 Jul 11. J Cyst Fibros. 2019. PMID: 31303382 Free article.

47

Fair selection of participants in clinical trials: The challenge to push the envelope further.

Davies JC, Scott S, Dobra R, Brendell R, Brownlee K, Carr SB, Cosgriff R, Simmonds NJ; London Network of Clinical Trials Accelerator Platform sites; Jahan R, Jones A, Matthews J, Brown S, Galono K, Miles K, Pao C, Shafi N, Watson D, Orchard C, Davies G, Pike K, Shah S, Bossley CJ, Fong T, Macedo P, Ruiz G, Waller M, Baker L. Davies JC, et al. Among authors: davies g. J Cyst Fibros. 2019 Sep;18(5):e48-e50. doi: 10.1016/j.jcf.2019.07.004. Epub 2019 Aug 9. J Cyst Fibros. 2019. PMID: 31405729 Free article. No abstract available.

48

Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?

Davies JC, Alton E, Simbo A, Murphy R, Seth I, Williams K, Somerville M, Jolly L, Morant S, Guest C. Davies JC, et al. Eur Respir J. 2019 Nov 7;54(5):1900970. doi: 10.1183/13993003.00970-2019. Print 2019 Nov. Eur Respir J. 2019. PMID: 31413160 Free article. No abstract available.

49

Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa.

Soren O, Rineh A, Silva DG, Cai Y, Howlin RP, Allan RN, Feelisch M, Davies JC, Connett GJ, Faust SN, Kelso MJ, Webb JS. Soren O, et al. Among authors: davies jc. J Antimicrob Chemother. 2020 Jan 1;75(1):117-125. doi: 10.1093/jac/dkz378. J Antimicrob Chemother. 2020. PMID: 31682251 Free PMC article.

50

Insights into the variability of nasal potential difference, a biomarker of CFTR activity.

Kyrilli S, Henry T, Wilschanski M, Fajac I, Davies JC, Jais JP, Sermet-Gaudelus I. Kyrilli S, et al. Among authors: davies jc. J Cyst Fibros. 2020 Jul;19(4):620-626. doi: 10.1016/j.jcf.2019.09.015. Epub 2019 Nov 4. J Cyst Fibros. 2020. PMID: 31699569 Free article.

51

Integrating the multiple breath washout test into international multicentre trials.

Saunders C, Jensen R, Robinson PD, Stanojevic S, Klingel M, Short C, Davies JC, Ratjen F. Saunders C, et al. Among authors: davies jc. J Cyst Fibros. 2020 Jul;19(4):602-607. doi: 10.1016/j.jcf.2019.11.006. Epub 2019 Nov 24. J Cyst Fibros. 2020. PMID: 31771900 Free article. Clinical Trial.

52

'Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020.

Langawi MA, Byrnes C, Davies JC, Hamouda S, Kabra M, Rached SZ, Sands D, Shteinberg M, Taylor-Cousar J, Tullis E, Wainwright C. Langawi MA, et al. Among authors: davies jc. J Cyst Fibros. 2020 Mar;19(2):184-193. doi: 10.1016/j.jcf.2020.02.021. Epub 2020 Mar 7. J Cyst Fibros. 2020. PMID: 32156627 Free article. Review.

53

Combination antifungal therapy for Scedosporium species in cystic fibrosis.

Bentley S, Davies JC, Carr SB, Balfour-Lynn IM. Bentley S, et al. Among authors: davies jc. Pediatr Pulmonol. 2020 Aug;55(8):1993-1995. doi: 10.1002/ppul.24789. Epub 2020 Apr 27. Pediatr Pulmonol. 2020. PMID: 32339450

54

Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor.

Nichols AL, Davies JC, Jones D, Carr SB. Nichols AL, et al. Among authors: davies jc. Paediatr Respir Rev. 2020 Sep;35:99-102. doi: 10.1016/j.prrv.2020.04.003. Epub 2020 Apr 14. Paediatr Respir Rev. 2020. PMID: 32386958 Review.

55

Building global development strategies for cf therapeutics during a transitional cftr modulator era.

Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Mayer-Hamblett N, et al. Among authors: davies jc. J Cyst Fibros. 2020 Sep;19(5):677-687. doi: 10.1016/j.jcf.2020.05.011. Epub 2020 Jun 7. J Cyst Fibros. 2020. PMID: 32522463 Free PMC article. Review.

56

Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view.

De Boeck K, Lee T, Amaral M, Drevinek P, Elborn JS, Fajac I, Kerem E, Davies JC. De Boeck K, et al. Among authors: davies jc. J Cyst Fibros. 2020 Sep;19(5):688-695. doi: 10.1016/j.jcf.2020.05.012. Epub 2020 Jun 8. J Cyst Fibros. 2020. PMID: 32527602 Free article.

57

Monitoring early stage lung disease in cystic fibrosis.

Nissenbaum C, Davies G, Horsley A, Davies JC. Nissenbaum C, et al. Among authors: davies g, davies jc. Curr Opin Pulm Med. 2020 Nov;26(6):671-678. doi: 10.1097/MCP.0000000000000732. Curr Opin Pulm Med. 2020. PMID: 32925367 Review.

58

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.

Davies JC, Sermet-Gaudelus I, Naehrlich L, Harris RS, Campbell D, Ahluwalia N, Short C, Haseltine E, Panorchan P, Saunders C, Owen CA, Wainwright CE; VX16-661-115 Investigator Group. Davies JC, et al. J Cyst Fibros. 2021 Jan;20(1):68-77. doi: 10.1016/j.jcf.2020.07.023. Epub 2020 Sep 21. J Cyst Fibros. 2021. PMID: 32967799 Free article. Clinical Trial.

59

Utility of lung clearance index in CF: What we know, what we don't know and musings on how to bridge the gap.

Short C, Saunders C, Davies JC. Short C, et al. Among authors: davies jc. J Cyst Fibros. 2020 Nov;19(6):852-855. doi: 10.1016/j.jcf.2020.10.007. Epub 2020 Nov 8. J Cyst Fibros. 2020. PMID: 33172755 Free article. No abstract available.

60

Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID).

Barben J, Castellani C, Munck A, Davies JC, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Mayell SJ, McColley S, Ooi CY, Proesmans M, Ren CL, Salinas D, Sands D, Sermet-Gaudelus I, Sommerburg O, Southern KW; European CF Society Neonatal Screening Working Group (ECFS NSWG). Barben J, et al. Among authors: davies jc. J Cyst Fibros. 2021 Sep;20(5):810-819. doi: 10.1016/j.jcf.2020.11.006. Epub 2020 Nov 27. J Cyst Fibros. 2021. PMID: 33257262 Free article. Review.

61

Pseudomonas aeruginosa in the Cystic Fibrosis Airway: Does It Deserve Its Reputation as a Predatory "Bully"?

Hughes DA, Price H, Rosenthal M, Davies JC. Hughes DA, et al. Among authors: davies jc. Am J Respir Crit Care Med. 2021 Apr 15;203(8):1027-1030. doi: 10.1164/rccm.202009-3639LE. Am J Respir Crit Care Med. 2021. PMID: 33264066 Free PMC article. No abstract available.

62

Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway.

Coates MS, Alton EWFW, Rapeport GW, Davies JC, Ito K. Coates MS, et al. Among authors: davies jc. PLoS One. 2021 Feb 1;16(2):e0246050. doi: 10.1371/journal.pone.0246050. eCollection 2021. PLoS One. 2021. PMID: 33524056 Free PMC article.

63

Discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in cystic fibrosis (CF) clinical trials.

Dobra RA, Boeri M, Elborn S, Kee F, Madge S, Davies JC. Dobra RA, et al. Among authors: davies jc. BMJ Open. 2021 Mar 2;11(3):e045803. doi: 10.1136/bmjopen-2020-045803. BMJ Open. 2021. PMID: 33653764 Free PMC article.

64

Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?

Dobra R, Davies G, Pike K, Strassle C, Allen L, Brendell R, Brownlee K, Carr SB, Simmonds NJ, Davies JC; London Network of Clinical Trials Accelerator Platform sites and affiliates. Dobra R, et al. Among authors: davies g, davies jc. J Cyst Fibros. 2021 Nov;20(6):978-985. doi: 10.1016/j.jcf.2021.03.027. Epub 2021 Apr 17. J Cyst Fibros. 2021. PMID: 33875366 Free article.

65

Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study.

Dobra R, Elborn JS, Madge S, Allen L, Boeri M, Kee F, Goundry S, Purcell T, Saunders C, Davies JC. Dobra R, et al. Among authors: davies jc. J Cyst Fibros. 2021 Nov;20(6):986-993. doi: 10.1016/j.jcf.2021.03.021. Epub 2021 Apr 21. J Cyst Fibros. 2021. PMID: 33895096 Free article.

66

Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis.

Bayfield KJ, Douglas TA, Rosenow T, Davies JC, Elborn SJ, Mall M, Paproki A, Ratjen F, Sly PD, Smyth AR, Stick S, Wainwright CE, Robinson PD. Bayfield KJ, et al. Among authors: davies jc. Thorax. 2021 Dec;76(12):1255-1265. doi: 10.1136/thoraxjnl-2020-216085. Epub 2021 Apr 29. Thorax. 2021. PMID: 33927017 Review.

67

Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients.

Kos R, Brinkman P, Neerincx AH, Paff T, Gerritsen MG, Lammers A, Kraneveld AD, Heijerman HGM, Janssens HM, Davies JC, Majoor CJ, Weersink EJ, Sterk PJ, Haarman EG, Bos LD, Maitland-van der Zee AH; Amsterdam Mucociliary Clearance Disease (AMCD) Research Group and the Amsterdam UMC Breath Research Group. Kos R, et al. Among authors: davies jc. J Cyst Fibros. 2022 Jan;21(1):e28-e34. doi: 10.1016/j.jcf.2021.04.015. Epub 2021 May 18. J Cyst Fibros. 2022. PMID: 34016557 Free article. Review.

68

Cystic fibrosis.

Shteinberg M, Haq IJ, Polineni D, Davies JC. Shteinberg M, et al. Among authors: davies jc. Lancet. 2021 Jun 5;397(10290):2195-2211. doi: 10.1016/S0140-6736(20)32542-3. Lancet. 2021. PMID: 34090606 Review.

69

Telemedicine and cystic fibrosis: Do we still need face-to-face clinics?

Dixon E, Dick K, Ollosson S, Jones D, Mattock H, Bentley S, Saunders C, Matthews J, Dobra B, King J, Edmondson C, Davies JC. Dixon E, et al. Among authors: davies jc. Paediatr Respir Rev. 2022 Jun;42:23-28. doi: 10.1016/j.prrv.2021.05.002. Epub 2021 May 19. Paediatr Respir Rev. 2022. PMID: 34215541 Review.

70

A Short extension to multiple breath washout provides additional signal of distal airway disease in people with CF: A pilot study.

Short C, Semple T, Saunders C, Hughes D, Irving S, Gardener L, Rosenthal M, Robinson PD, Davies JC. Short C, et al. Among authors: davies jc. J Cyst Fibros. 2022 Jan;21(1):146-154. doi: 10.1016/j.jcf.2021.06.013. Epub 2021 Jul 16. J Cyst Fibros. 2022. PMID: 34275757 Free article.

71

Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.

Goss CH, Fajac I, Jain R, Seibold W, Gupta A, Hsu MC, Sutharsan S, Davies JC, Mall MA. Goss CH, et al. Among authors: davies jc. Eur Respir J. 2022 Feb 17;59(2):2100746. doi: 10.1183/13993003.00746-2021. Print 2022 Feb. Eur Respir J. 2022. PMID: 34385272 Free PMC article. Clinical Trial.

72

Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.

Derichs N, Taylor-Cousar JL, Davies JC, Fajac I, Tullis E, Nazareth D, Downey DG, Rosenbluth D, Malfroot A, Saunders C, Jensen R, Solomon GM, Vermeulen F, Kaiser A, Willmann S, Saleh S, Droebner K, Sandner P, Bear CE, Hoffmann A, Ratjen F, Rowe SM; Rio-CF Study Group. Derichs N, et al. Among authors: davies jc. J Cyst Fibros. 2021 Nov;20(6):1018-1025. doi: 10.1016/j.jcf.2021.07.015. Epub 2021 Aug 19. J Cyst Fibros. 2021. PMID: 34419414 Free article. Clinical Trial.

73

Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis.

Bentley S, Davies JC, Gastine S, Donovan J, Standing JF. Bentley S, et al. Among authors: davies jc. J Antimicrob Chemother. 2021 Nov 12;76(12):3247-3254. doi: 10.1093/jac/dkab312. J Antimicrob Chemother. 2021. PMID: 34458906 Free PMC article.

74

Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials.

Robinson PD, Jensen R, Seeto RA, Stanojevic S, Saunders C, Short C, Davies JC, Ratjen F. Robinson PD, et al. Among authors: davies jc. J Cyst Fibros. 2022 May;21(3):e204-e207. doi: 10.1016/j.jcf.2021.08.033. Epub 2021 Sep 12. J Cyst Fibros. 2022. PMID: 34526221 No abstract available.

75

The feasibility of home monitoring of young people with cystic fibrosis: Results from CLIMB-CF.

Edmondson C, Westrupp N, Seddon P, Olden C, Wallis C, Dawson C, Brodlie M, Baxter F, McCormick J, MacFarlane S, Rice D, Macleod A, Brooker R, Connon M, Ghayyda S, Blaikie L, Thursfield R, Brown L, Price A, Fleischer E, Itterman J, Hughes D, Barrett P, Surette M, Donnelly C, Mateos-Corral D, Padley G, Wallenburg J, Brownlee K, Alton EWFW, Bush A, Davies JC. Edmondson C, et al. Among authors: davies jc. J Cyst Fibros. 2022 Jan;21(1):70-77. doi: 10.1016/j.jcf.2021.09.018. Epub 2021 Oct 8. J Cyst Fibros. 2022. PMID: 34635459 Free article.

76

The life rafts sailed; Now let's take stock and set the course ahead (Commentary).

Davies JC. Davies JC. J Cyst Fibros. 2021 Dec;20 Suppl 3:29-30. doi: 10.1016/j.jcf.2021.08.022. J Cyst Fibros. 2021. PMID: 34930538 Free PMC article. No abstract available.

77

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.

Sawicki GS, Chilvers M, McNamara J, Naehrlich L, Saunders C, Sermet-Gaudelus I, Wainwright CE, Ahluwalia N, Campbell D, Harris RS, Paz-Diaz H, Shih JL, Davies JC. Sawicki GS, et al. Among authors: davies jc. J Cyst Fibros. 2022 Jul;21(4):675-683. doi: 10.1016/j.jcf.2022.02.003. Epub 2022 Feb 18. J Cyst Fibros. 2022. PMID: 35190292 Free article. Clinical Trial.

78

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.

King JA, Nichols AL, Bentley S, Carr SB, Davies JC. King JA, et al. Among authors: davies jc. Paediatr Drugs. 2022 Jul;24(4):321-333. doi: 10.1007/s40272-022-00509-y. Epub 2022 May 16. Paediatr Drugs. 2022. PMID: 35570261 Review.

79

Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.

Murphy RA, Coates M, Thrane S, Sabnis A, Harrison J, Schelenz S, Edwards AM, Vorup-Jensen T, Davies JC. Murphy RA, et al. Among authors: davies jc. Microbiol Spectr. 2022 Aug 31;10(4):e0081322. doi: 10.1128/spectrum.00813-22. Epub 2022 Jun 21. Microbiol Spectr. 2022. PMID: 35727066 Free PMC article.

80

An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples.

Hughes DA, Rosenthal M, Cuthbertson L, Ramadan N, Felton I, Simmonds NJ, Loebinger MR, Price H, Armstrong-James D, Elborn JS, Cookson WO, Moffatt MF, Davies JC. Hughes DA, et al. Among authors: davies jc. J Cyst Fibros. 2023 Mar;22(2):320-326. doi: 10.1016/j.jcf.2022.07.009. Epub 2022 Jul 22. J Cyst Fibros. 2023. PMID: 35871975 Free article.

81

Pseudomonas aeruginosa in the Cystic Fibrosis Lung.

King J, Murphy R, Davies JC. King J, et al. Among authors: davies jc. Adv Exp Med Biol. 2022;1386:347-369. doi: 10.1007/978-3-031-08491-1_13. Adv Exp Med Biol. 2022. PMID: 36258079

82

New concepts in antimicrobial resistance in cystic fibrosis respiratory infections.

Drevinek P, Canton R, Johansen HK, Hoffman L, Coenye T, Burgel PR, Davies JC. Drevinek P, et al. Among authors: davies jc. J Cyst Fibros. 2022 Nov;21(6):937-945. doi: 10.1016/j.jcf.2022.10.005. Epub 2022 Oct 18. J Cyst Fibros. 2022. PMID: 36270946 Free article. Review.

83

Future therapies for cystic fibrosis.

Allen L, Allen L, Carr SB, Davies G, Downey D, Egan M, Forton JT, Gray R, Haworth C, Horsley A, Smyth AR, Southern KW, Davies JC. Allen L, et al. Among authors: davies g, davies jc. Nat Commun. 2023 Feb 8;14(1):693. doi: 10.1038/s41467-023-36244-2. Nat Commun. 2023. PMID: 36755044 Free PMC article. Review.

84

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.

Southern KW, Castellani C, Lammertyn E, Smyth A, VanDevanter D, van Koningsbruggen-Rietschel S, Barben J, Bevan A, Brokaar E, Collins S, Connett GJ, Daniels TWV, Davies J, Declercq D, Gartner S, Gramegna A, Hamilton N, Hauser J, Kashirskaya N, Kessler L, Lowdon J, Makukh H, Martin C, Morrison L, Nazareth D, Noordhoek J, O'Neill C, Owen E, Oxley H, Raraigh KS, Raynal C, Robinson K, Roehmel J, Schwarz C, Sermet I, Shteinberg M, Sinha I, Takawira C, van Mourik P, Verkleij M, Waller MD, Duff A. Southern KW, et al. J Cyst Fibros. 2023 Jan;22(1):17-30. doi: 10.1016/j.jcf.2022.10.002. Epub 2022 Oct 28. J Cyst Fibros. 2023. PMID: 36916675 Free article.

85

Chronic rhinosinusitis in the era of CFTR modulator therapy.

Stone RG, Short C, Davies JC, McNally P. Stone RG, et al. Among authors: davies jc. J Cyst Fibros. 2023 Sep 8:S1569-1993(23)00877-9. doi: 10.1016/j.jcf.2023.08.009. Online ahead of print. J Cyst Fibros. 2023. PMID: 37690973 Free article. Review.

86

Standards for the care of people with cystic fibrosis (CF).

Southern KW, Burgel PR, Castellani C, De Boeck K, Davies JC, Dunlevy F, Fajac I, Gramegna A, Lammertyn E, Middleton PG, Ratjen F, van Koningsbruggen-Rietschel S. Southern KW, et al. Among authors: davies jc. J Cyst Fibros. 2023 Nov;22(6):961-962. doi: 10.1016/j.jcf.2023.09.009. Epub 2023 Oct 3. J Cyst Fibros. 2023. PMID: 37798158 No abstract available.

87

A discrete choice experiment to quantify the influence of trial features on the decision to participate in cystic fibrosis trials.

Dobra R, Davies J, Elborn S, Kee F, Madge S, Boeri M. Dobra R, et al. J Cyst Fibros. 2024 Jan;23(1):73-79. doi: 10.1016/j.jcf.2023.04.024. Epub 2023 Dec 1. J Cyst Fibros. 2024. PMID: 38042750

88

Chronicity Counts: The Impact of P. aeruginosa, S. aureus, and Co-Infection in Cystic Fibrosis.

Mossop M, Ish-Horowicz J, Hughes D, Dobra R, Cunanan AG, Rosenthal M, Carr SB, Ramadan N, Nolan LM, Davies JC. Mossop M, et al. Among authors: davies jc. Am J Respir Crit Care Med. 2024 Feb 29. doi: 10.1164/rccm.202312-2326LE. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 38422389 No abstract available.

89

What is cystic fibrosis screen positive inconclusive diagnosis? And what is it not?

Devoy E, Hughes D, Alharbi AF, Francis J, Davies JC. Devoy E, et al. Among authors: davies jc. Arch Dis Child Educ Pract Ed. 2024 Mar 7:edpract-2023-326767. doi: 10.1136/archdischild-2023-326767. Online ahead of print. Arch Dis Child Educ Pract Ed. 2024. PMID: 38453427

90

Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis.

McNally P, Singh A, McColley SA, Davies JC, Higgins M, Liu M, Lu J, Rodriguez-Romero V, Shih JL, Rosenfeld M; VX15-770-124 Study Group. McNally P, et al. Among authors: davies jc. J Cyst Fibros. 2024 Apr 4:S1569-1993(24)00042-0. doi: 10.1016/j.jcf.2024.03.012. Online ahead of print. J Cyst Fibros. 2024. PMID: 38580563 Free article.

91

Retrospective review of the effects of rhDNase in children with cystic fibrosis.

Davies J, Trindade MT, Wallis C, Rosenthal M, Crawford O, Bush A. Davies J, et al. Pediatr Pulmonol. 1997 Apr;23(4):243-8. doi: 10.1002/(sici)1099-0496(199704)23:4<243::aid-ppul1>3.0.co;2-n. Pediatr Pulmonol. 1997. PMID: 9141109

92

CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium.

Davies JC, Stern M, Dewar A, Caplen NJ, Munkonge FM, Pitt T, Sorgi F, Huang L, Bush A, Geddes DM, Alton EW. Davies JC, et al. Am J Respir Cell Mol Biol. 1997 Jun;16(6):657-63. doi: 10.1165/ajrcmb.16.6.9191467. Am J Respir Cell Mol Biol. 1997. PMID: 9191467

93

The clinical use of rhDNAse.

Davies J, Trindale M, Wallis C, Rosenthal M, Bush A. Davies J, et al. Pediatr Pulmonol Suppl. 1997;16:273-4. doi: 10.1002/ppul.19502308141. Pediatr Pulmonol Suppl. 1997. PMID: 9443309 Review. No abstract available.

94

Prospects for gene therapy for cystic fibrosis.

Davies JC, Geddes DM, Alton EW. Davies JC, et al. Mol Med Today. 1998 Jul;4(7):292-9. doi: 10.1016/s1357-4310(98)01265-9. Mol Med Today. 1998. PMID: 9743990 Review.

95

Gene therapy for cystic fibrosis.

Davies JC, Geddes DM, Alton EW. Davies JC, et al. J Gene Med. 2001 Sep-Oct;3(5):409-17. doi: 10.1002/jgm.200. J Gene Med. 2001. PMID: 11601754 Review.

96

New therapeutic approaches for cystic fibrosis lung disease.

Davies JC. Davies JC. J R Soc Med. 2002;95 Suppl 41(Suppl 41):58-67. J R Soc Med. 2002. PMID: 12216276 Free PMC article. Review. No abstract available.

97

Modifier genes in cystic fibrosis.

Davies JC. Davies JC. Pediatr Pulmonol Suppl. 2004;26:86-7. doi: 10.1002/ppul.70062. Pediatr Pulmonol Suppl. 2004. PMID: 15029608 Review. No abstract available.

98

Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect.

McShane D, Davies JC, Wodehouse T, Bush A, Geddes D, Alton EW. McShane D, et al. Among authors: davies jc. Eur Respir J. 2004 Jul;24(1):95-100. doi: 10.1183/09031936.04.00097503. Eur Respir J. 2004. PMID: 15293610 Free article.

99

Potential difference measurements in the lower airway of children with and without cystic fibrosis.

Davies JC, Davies M, McShane D, Smith S, Chadwick S, Jaffe A, Farley R, Collins L, Bush A, Scallon M, Pepper J, Geddes DM, Alton EW. Davies JC, et al. Among authors: davies m. Am J Respir Crit Care Med. 2005 May 1;171(9):1015-9. doi: 10.1164/rccm.200408-1116OC. Epub 2005 Jan 7. Am J Respir Crit Care Med. 2005. PMID: 15640364

100

Modifier genes in cystic fibrosis.

Davies JC, Griesenbach U, Alton E. Davies JC, et al. Pediatr Pulmonol. 2005 May;39(5):383-91. doi: 10.1002/ppul.20198. Pediatr Pulmonol. 2005. PMID: 15765543 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

359 results

Search Page